Viking Therapeutics Inc (NASDAQ:VKTX) has received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $23.48.
VKTX has been the subject of several recent analyst reports. BidaskClub lowered Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 6th. Maxim Group lowered their price target on Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Leerink Swann initiated coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a “market perform” rating and a $10.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, March 29th. Finally, Svb Leerink initiated coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a “mkt perform” rating for the company.
Large investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Viking Therapeutics in the 4th quarter worth about $30,000. Lindbrook Capital LLC purchased a new position in Viking Therapeutics in the 4th quarter worth about $36,000. US Bancorp DE purchased a new position in Viking Therapeutics in the 1st quarter worth about $41,000. Great West Life Assurance Co. Can purchased a new position in Viking Therapeutics in the 4th quarter worth about $53,000. Finally, Nisa Investment Advisors LLC purchased a new position in Viking Therapeutics in the 4th quarter worth about $60,000. 63.58% of the stock is owned by institutional investors and hedge funds.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. As a group, equities analysts anticipate that Viking Therapeutics will post -0.41 EPS for the current fiscal year.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Recommended Story: Investing in Dividend Stocks
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.